Seasoned professional with 20+ years experience in pharmaceutical companies, which twelve years in major Top 10, Chris has acquired Global experience at the headquarter of US company for more than 5 years leading a strategic role as Head of Global Pricing & Market Access for a portfolio composed by marketed brands and new products in oncology, a universally acknowledged critical sector for the future growth of pharmaceutical companies. In this role, Chris gained worldwide access and reimbursement for Alimta in 2nd and 1st line non-squamous NSCLC, as well as for switch and continuation maintenance therapy in non-squamous NSCLC, while maximizing the revenue with Gemzar facing a patent loss. Preparing for the future, he integrated the ImClone business and developed the strategy to launch Necitumumab in squamous NSCLC and Ramucirumab in mGC, mHCC, mCRC and 2nd line NSCLC.